NCT05379829 - A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2024

Conditions

Chronic Kidney Disease and Systemic Inflammation

Interventions

DRUG

Ziltivekimab

Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).

DRUG

Placebo

Participants will be administered 3 doses s.c. Q4W.

Trial Locations (6)

Peking University Third Hospital, Beijing

Beijing Hospital, Beijing

Zhongda Hospital Southeast University-Nephrology, Nanjing

Zhongda Hospital Southeast University-Neurology, Nanjing

The First Affiliated Hospital of Soochow University-Endocrinology, Suzhou

The First Affiliated Hospital Of Soochow University, Suzhou